How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,375 results for

Cushing Response

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. The reliability of screening tests for Cushing's syndrome in patients with chronic renal failure: a systematic review

The reliability of screening tests for Cushing's syndrome in patients with chronic renal failure: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2016 PROSPERO

62. Systemic vascular responses to increased intracranial pressure: 2 The `Cushing' response in the presence of intracranial space-occupying lesions: systemic and cerebral haemodynamic studies in the dog and the baboon Full Text available with Trip Pro

Systemic vascular responses to increased intracranial pressure: 2 The `Cushing' response in the presence of intracranial space-occupying lesions: systemic and cerebral haemodynamic studies in the dog and the baboon Continued expansion of an artificial space-occupying lesion produced further increases in mean supratentorial and infratentorial pressures associated with increases in mean arterial pressure, heart rate, and systemic vascular resistance-the `Cushing' or systemic hypertensive response (...) . These primary changes resulted in an increase in transtentorial pressure gradient and a decrease in arrhythmia index. Immediately before the onset of the systemic hypertensive response, supratentorial perfusion pressure was low, and the period of systemic hypertension did not appear to produce any worthwhile improvement in the perfusion pressure or in the blood flow in the supratentorial compartment. The studies demonstrated also that the systemic hypertensive response was a pre-terminal event

1977 Journal of neurology, neurosurgery, and psychiatry

63. The Cortisol Awakening Response (CAR) is blunted in patients with active Cushing's disease. Full Text available with Trip Pro

The Cortisol Awakening Response (CAR) is blunted in patients with active Cushing's disease. Cortisol awakening response (CAR) is a rapid increase of cortisol levels within 30-45 min after awakening.This study evaluates CAR compared with cortisol circadian rhythm in active and in remission Cushing's disease (CD).We evaluated healthy controls (HC, n=19), obese (OB, n=10), in remission (n=08), and active CD patients (n=10). Salivary free cortisol (SF) was determined at 0800, 1100, 1700, 2000

2013 European Journal of Endocrinology

64. The Accuracy of Late Night Urinary Free Cortisol/Creatinine and Hair Cortisol in Cushing's Syndrome Diagnosis

(100). Please remove one or more studies before adding more. The Accuracy of Late Night Urinary Free Cortisol/Creatinine and Hair Cortisol in Cushing's Syndrome Diagnosis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier (...) The Accuracy of Late Night Urinary Free Cortisol/Creatinine and Hair Cortisol in Cushing's Syndrome Diagnosis The Accuracy of Late Night Urinary Free Cortisol/Creatinine and Hair Cortisol in Cushing's Syndrome Diagnosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

2016 Clinical Trials

65. Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome

remove one or more studies before adding more. Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome (RE-KLAIM) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02663609 Recruitment Status : Completed First Posted : January 26, 2016 Last Update Posted (...) : November 30, 2018 Sponsor: Corcept Therapeutics Information provided by (Responsible Party): Corcept Therapeutics Study Details Study Description Go to Brief Summary: Chart review study to collect patient data from medical charts of patients who have been treated with Korlym® for the treatment of ACTH independent adrenal Cushing's Syndrome. Condition or disease Intervention/treatment Cushing's Syndrome Other: No intervention Detailed Description: A retrospective, multi-center, chart review study

2016 Clinical Trials

66. Targeting the ERK pathway for the treatment of Cushing's disease Full Text available with Trip Pro

serve as a predictive biomarker of MEK-162 corticotroph tumor responsiveness. Additionally, MEK-162 treatment reduced TR4 protein expression and blocked recruitment of TR4 to bind its consensus site on the POMC promoter (-854bp to -637bp), elucidating multiple mechanisms to control TR4 corticotroph tumor actions. In a murine corticotroph tumor in vivo model of Cushing's disease, MEK-162 treatment inhibited tumor growth and reduced tumor-derived circulating plasma ACTH, and corticosterone levels (...) Targeting the ERK pathway for the treatment of Cushing's disease We recently demonstrated that the orphan nuclear receptor testicular receptor 4 (TR4) is a potent regulator of corticotroph tumor growth and hormone secretion. The Ras/Raf/MEK/ERK pathway is commonly overactivated in human tumors and we have demonstrated that corticotroph tumor TR4 is activated by ERK1/2-mediated phosphorylation. We evaluated effects of MEK-162, a selective, non-ATP-competitive allosteric inhibitor of MEK1/2

2016 Oncotarget

67. Systemic Sarcoidosis Unmasked by Cushing's Disease Surgical Treatment Full Text available with Trip Pro

Systemic Sarcoidosis Unmasked by Cushing's Disease Surgical Treatment Diseases responsive to glucocorticoids, like sarcoidosis, are rarely masked by Cushing's syndrome. An ACTH secreting pituitary adenoma is a possible cause of Cushing's syndrome and its resection can make a subclinical sarcoidosis clear. Only few cases of sarcoidosis following the treatment of hypercortisolism are reported in literature. We report a case of sarcoidosis after the resection of an ACTH secreting pituitary adenoma.

2016 Case reports in medicine

68. Unmasking sarcoidosis following surgery for Cushing disease Full Text available with Trip Pro

of underlying sarcoidosis was substantiated by lung imaging and elevated plasma interleukin (IL)-2 receptor. One month later, the lesions spontaneously resolved without therapy other than maintenance glucocorticoid replacement. Physicians should be aware that patients undergoing successful treatment of Cushing syndrome may have a flare-up or emergence of a corticosteroid-responsive disease. (...) Unmasking sarcoidosis following surgery for Cushing disease We present a patient with Cushing disease apparently suppressing sarcoidosis, which was unmasked following surgical resection of a pituitary adrenocorticotropin (ACTH)-producing microadenoma. Case report and a short review of the literature published in this area. A 46-year-old Caucasian woman presented with symptoms of hypercortisolism such as progressive weight gain, Cushingoid appearance, proximal myopathy, easy bruising

2016 Dermato-endocrinology

69. The desmopressin test predicts better than basal cortisol the long-term surgical outcome of Cushing's disease. Full Text available with Trip Pro

The desmopressin test predicts better than basal cortisol the long-term surgical outcome of Cushing's disease. Cushing's disease (CD) has a significant relapse rate after successful transsphenoidal surgery (TSS). Many CD patients respond aberrantly to the desmopressin test (DT). Disappearance of this response after surgery may suggest complete removal of abnormal corticotrophs and a lower possibility of recurrence.The utility of postoperative DT to predict long-term outcome compared (...) a sensitivity of 97% to detect remission. Comparison of Kaplan-Meier curves showed that ΔCort <7.4 μg/dL was associated with remission, whereas ΔCort ≥7.4 μg/dL had a hazard ratio of recurrence of 24.7 (95% confidence interval, 10.6-448.5) at 60 months (median).Loss of desmopressin response indicates favorable prognosis and, if used in addition to basal cortisol levels, improves the accuracy of the postoperative assessment of CD.

2016 Journal of Clinical Endocrinology and Metabolism

70. Cabergoline for Cushing's disease: a large retrospective multicenter study. Full Text available with Trip Pro

Cabergoline for Cushing's disease: a large retrospective multicenter study. The efficacy of cabergoline in Cushing's disease (CD) is controversial. The aim of this study was to assess the efficacy and tolerability of cabergoline in a large contemporary cohort of patients with CD.We conducted a retrospective multicenter study from thirteen French and Belgian university hospitals.Sixty-two patients with CD received cabergoline monotherapy or add-on therapy. Symptom score, biological markers (...) during the first year of treatment with cabergoline at 1.0 mg/week (0.5-3.5).About 20-25% of CD patients are good responders to cabergoline therapy allowing long-term control of hypercortisolism at relatively low dosages and with acceptable tolerability. No single parameter, including the baseline UFC and prolactin levels, predicted the response to cabergoline.© 2017 European Society of Endocrinology.

2016 European Journal of Endocrinology

71. Saliva Cortisol Measurement as a Screening Test for Suspicious Cushings Syndrome in Children.

or more studies before adding more. Saliva Cortisol Measurement as a Screening Test for Suspicious Cushings Syndrome in Children. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02646553 Recruitment Status : Recruiting (...) First Posted : January 5, 2016 Last Update Posted : August 16, 2017 See Sponsor: Haukeland University Hospital Information provided by (Responsible Party): Haukeland University Hospital Study Details Study Description Go to Brief Summary: Cortisol overproduction ( Cushings syndrome) is a condition where the patient have a special fat distribution, with accumulation of fat around the abdomen and in the neck, with thinner limbs and weak musculature. The condition can be difficult to separate from

2016 Clinical Trials

72. Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease

Evaluation of Osilodrostat in Cushing's Disease (LINC-4) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02697734 Recruitment Status : Recruiting First Posted : March 3, 2016 Last Update Posted : September 25, 2018 See Sponsor (...) : Novartis Pharmaceuticals Information provided by (Responsible Party): Novartis ( Novartis Pharmaceuticals ) Study Details Study Description Go to Brief Summary: Purpose of study is to aim to confirm efficacy and safety of osilodrostat for the treatment of patients with Cushing's disease who are candidates for medical therapy Condition or disease Intervention/treatment Phase Cushing's Disease Drug: osilodrostat Drug: osilodrostat Placebo Phase 3 Study Design Go to Layout table for study information

2016 Clinical Trials

73. Study to Evaluate CORT125134 in Patients With Cushing's Syndrome

in Patients With Cushing's Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02804750 Recruitment Status : Completed First Posted : June 17, 2016 Last Update Posted : November 15, 2018 Sponsor: Corcept Therapeutics Information provided by (Responsible Party): Corcept Therapeutics Study Details Study (...) Responsible Party: Corcept Therapeutics ClinicalTrials.gov Identifier: Other Study ID Numbers: CORT125134-451 First Posted: June 17, 2016 Last Update Posted: November 15, 2018 Last Verified: November 2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Undecided Keywords provided by Corcept Therapeutics: Cushing's Syndrome Cushing's Disease Cushings Hypercortisolemia Cushingoid Type 2 Diabetes Impaired Glucose Intolerance Hypertension Adrenal Corticotrophic Hormone (ACTH

2016 Clinical Trials

74. Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery

or more studies before adding more. Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02922257 Recruitment Status : Completed First Posted : October 4, 2016 Last Update Posted : January 24, 2019 Sponsor (...) : Corcept Therapeutics Information provided by (Responsible Party): Corcept Therapeutics Study Details Study Description Go to Brief Summary: This study will investigate the potential for FK506 binding protein 5 (FKBP5) (and other gene expression markers, for example pentraxin 3 [PTX-3], serum/glucocorticoid regulated kinase 1 [SGK1], and glycogen synthase kinase 3 beta [GSK3b]) to be developed as a biomarker for use in diagnosis of Cushing's syndrome, assessment of effectiveness of medical or surgical

2016 Clinical Trials

75. Vascular health in patients in remission of Cushing's syndrome is comparable to that in BMI-matched controls. Full Text available with Trip Pro

Vascular health in patients in remission of Cushing's syndrome is comparable to that in BMI-matched controls. In active Cushing's syndrome (CS), patients suffer from endothelial dysfunction and premature atherosclerosis. However, it is uncertain to what extent vascular health recovers after long-term remission. This is highly relevant because this topic relates to future development of cardiovascular disease.The objective of the study was to investigate whether micro- and macrovascular health (...) ), endothelium-dependent and -independent vasodilatation was studied in conduit arteries (flow mediated dilation of the brachial artery) and forearm skeletal muscle resistance arteries (vasodilator response to intraarterial acetylcholine, sodium-nitroprusside, and NG-monomethyl-L-arginine using venous occlusion plethysmography).There were no significant differences between the outcome measures of vascular health of patients and controls in groups A and B.The vascular health of patients in long-term remission

2016 Journal of Clinical Endocrinology and Metabolism

76. Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects

studies (100). Please remove one or more studies before adding more. Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02574793 Recruitment Status : Completed First Posted : October 14, 2015 (...) Last Update Posted : January 23, 2018 Sponsor: Huashan Hospital Information provided by (Responsible Party): xiaolong zhao, Huashan Hospital Study Details Study Description Go to Brief Summary: Glucose fluctuations present not only in patients with diabetes mellitus but also in subjects with normal glucose tolerance or impaired glucose regulation. People with Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome are at risk of impaired glucose metabolism. Glycemic variability is poorly

2015 Clinical Trials

77. Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease

. Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease (MEMOCUSH) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02603653 Recruitment Status : Unknown Verified November 2015 by Institut National de la Santé Et de la Recherche Médicale, France. Recruitment status was: Not yet (...) recruiting First Posted : November 13, 2015 Last Update Posted : November 13, 2015 Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Information provided by (Responsible Party): Institut National de la Santé Et de la Recherche Médicale, France Study Details Study Description Go to Brief Summary: Cushing's disease is a state of chronic endogenous glucocorticoid excess. Cushing's disease is responsible for increased morbidity and mortality. Recent studies have pinpointed

2015 Clinical Trials

78. Cushing's Disease Complications

Cushing's Disease Complications Cushing's Disease Complications - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Cushing's Disease Complications (COMPLICUSHING) The safety and scientific validity (...) of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02568982 Recruitment Status : Recruiting First Posted : October 6, 2015 Last Update Posted : March 19, 2018 See Sponsor: Assistance Publique - Hôpitaux de Paris Information provided by (Responsible Party): Assistance

2015 Clinical Trials

79. Dilated Cardiomyopathy Revealing Cushing Disease: A Case Report and Literature Review. Full Text available with Trip Pro

Dilated Cardiomyopathy Revealing Cushing Disease: A Case Report and Literature Review. Cardiovascular impairments are frequent in Cushing's syndrome and the hypercortisolism can result in cardiac structural and functional changes that lead in rare cases to dilated cardiomyopathy (DCM). Such cardiac impairment may be reversible in response to a eucortisolaemic state.A 43-year-old man with a medical past of hypertension and history of smoking presented to the emergency department with global (...) heart failure. Coronary angiography showed a significant stenosis of a marginal branch and cardiac MRI revealed a nonischemic DCM. The left ventricular ejection fraction (LVEF) was estimated as 28% to 30%. Clinicobiological features and pituitary imaging pointed toward Cushing's disease and administration of adrenolytic drugs (metyrapone and ketoconazole) was initiated. Despite the normalization of cortisol which had been achieved 2 months later, the patient presented an acute heart failure

2015 Medicine

80. The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease. Full Text available with Trip Pro

The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease. Somatic mutations in the ubiquitin-specific peptidase USP8 gene were recently detected in one- to two-third(s) of corticotroph adenomas of Cushing's disease (CD). These mutations may lead to the deubiquitination of EGFR, thereby increasing EGFR signaling, which has been implicated in ACTH hypersecretion.Our objective was to determine the impact of USP8 mutations on the clinicopathological (...) mutations may predict favorable responses to the somatostatin analog pasireotide, which exhibits high affinity for SSTR5. In contrast, non-mutated aggressive tumors such as CCA may respond better to the alkylating agent temozolomide because of their significantly weak expression of MGMT.© 2016 European Society of Endocrinology.

2015 European Journal of Endocrinology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>